Ibrutinib, an efficacious Bruton’s tyrosine kinase (BTK) inhibitor endorsed by the US Food and Drug Administration for treating chronic lymphocytic leukemia, mantle cell lymphoma, and so on [4,5], is linked to elevated risks of atrial fibrillation (AF) and hemorrhagic complications. Here, BTK is linked to B-cell chronic lymphocytic leukemia.